Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Notified -
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-06-02, 12:00
